Cargando…
Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial
BACKGROUND: Hypoxia-inducible-factor-1α (HIF-1α) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic-inflammatory response. Functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs51665...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982006/ https://www.ncbi.nlm.nih.gov/pubmed/27515179 http://dx.doi.org/10.1186/s12871-016-0225-y |
_version_ | 1782447693090521088 |
---|---|
author | Höcker, Annika Rabeling, Miriam Bick, Alexandra Cox, Linda Kreuzer, Maximiliane Engler, Andrea Walstein, Kai Bachmann, Hagen S. Jöckel, Karl-Heinz Eisele, Lewin Adamzik, Michael Peters, Jürgen Schäfer, Simon T. |
author_facet | Höcker, Annika Rabeling, Miriam Bick, Alexandra Cox, Linda Kreuzer, Maximiliane Engler, Andrea Walstein, Kai Bachmann, Hagen S. Jöckel, Karl-Heinz Eisele, Lewin Adamzik, Michael Peters, Jürgen Schäfer, Simon T. |
author_sort | Höcker, Annika |
collection | PubMed |
description | BACKGROUND: Hypoxia-inducible-factor-1α (HIF-1α) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic-inflammatory response. Functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs516651 and T/C; SNP rs480902) are associated with altered HIF-1α mRNA nuclear translocation and an altered adaptation to hypoxia. Furthermore, the HIF system is important in surviving inflammatory disorders and sepsis. Thus, we tested the hypotheses, that SNPs in the HIF-1α or PHD2 genes are (1) common in Caucasians, with 2) the HIF-1α genetic variant being associated with an altered HIF-1α mRNA expression; and 3) independent risk factors for 30-day mortality in severe sepsis. METHODS: After ethics approval, 128 septic patients (Caucasian descent) were included prospectively within 24 h after first diagnosing sepsis. Patients characteristics and severity of illness (simplified acute physiology score II), genotypes (Taqman assay), and their influence on leukocyte HIF-1α-mRNA-expression (Real-Time PCR) and 30-day mortality were determined. RESULTS: Frequencies were 0.8 % for homozygous HIF-1α TT-carriers (CT 17.6 %; CC 81.6 %), 2.5 % for homozygous PHD2 SNP rs516651 TT-allele carriers (CT 17.5 % and CC 80 %), and 9.4 % for homozygous PHD2 SNP rs480902 TT-allele carriers (CT 34.4 % and CC 56.3 %). While HIF-1α T-allele carriers had a borderline decrease in HIF-1α-mRNA-expression (p = 0.06) neither HIF-1α nor PHD2 SNPs were (independent) risk factors for 30-day mortality. CONCLUSIONS: Genetic variants in HIF-1α and PHD2 genes exist in Caucasians but do not appear to alter 30-day mortality in sepsis. |
format | Online Article Text |
id | pubmed-4982006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49820062016-08-13 Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial Höcker, Annika Rabeling, Miriam Bick, Alexandra Cox, Linda Kreuzer, Maximiliane Engler, Andrea Walstein, Kai Bachmann, Hagen S. Jöckel, Karl-Heinz Eisele, Lewin Adamzik, Michael Peters, Jürgen Schäfer, Simon T. BMC Anesthesiol Research Article BACKGROUND: Hypoxia-inducible-factor-1α (HIF-1α) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic-inflammatory response. Functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs516651 and T/C; SNP rs480902) are associated with altered HIF-1α mRNA nuclear translocation and an altered adaptation to hypoxia. Furthermore, the HIF system is important in surviving inflammatory disorders and sepsis. Thus, we tested the hypotheses, that SNPs in the HIF-1α or PHD2 genes are (1) common in Caucasians, with 2) the HIF-1α genetic variant being associated with an altered HIF-1α mRNA expression; and 3) independent risk factors for 30-day mortality in severe sepsis. METHODS: After ethics approval, 128 septic patients (Caucasian descent) were included prospectively within 24 h after first diagnosing sepsis. Patients characteristics and severity of illness (simplified acute physiology score II), genotypes (Taqman assay), and their influence on leukocyte HIF-1α-mRNA-expression (Real-Time PCR) and 30-day mortality were determined. RESULTS: Frequencies were 0.8 % for homozygous HIF-1α TT-carriers (CT 17.6 %; CC 81.6 %), 2.5 % for homozygous PHD2 SNP rs516651 TT-allele carriers (CT 17.5 % and CC 80 %), and 9.4 % for homozygous PHD2 SNP rs480902 TT-allele carriers (CT 34.4 % and CC 56.3 %). While HIF-1α T-allele carriers had a borderline decrease in HIF-1α-mRNA-expression (p = 0.06) neither HIF-1α nor PHD2 SNPs were (independent) risk factors for 30-day mortality. CONCLUSIONS: Genetic variants in HIF-1α and PHD2 genes exist in Caucasians but do not appear to alter 30-day mortality in sepsis. BioMed Central 2016-08-11 /pmc/articles/PMC4982006/ /pubmed/27515179 http://dx.doi.org/10.1186/s12871-016-0225-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Höcker, Annika Rabeling, Miriam Bick, Alexandra Cox, Linda Kreuzer, Maximiliane Engler, Andrea Walstein, Kai Bachmann, Hagen S. Jöckel, Karl-Heinz Eisele, Lewin Adamzik, Michael Peters, Jürgen Schäfer, Simon T. Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial |
title | Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial |
title_full | Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial |
title_fullStr | Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial |
title_full_unstemmed | Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial |
title_short | Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial |
title_sort | hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982006/ https://www.ncbi.nlm.nih.gov/pubmed/27515179 http://dx.doi.org/10.1186/s12871-016-0225-y |
work_keys_str_mv | AT hockerannika hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT rabelingmiriam hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT bickalexandra hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT coxlinda hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT kreuzermaximiliane hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT englerandrea hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT walsteinkai hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT bachmannhagens hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT jockelkarlheinz hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT eiselelewin hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT adamzikmichael hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT petersjurgen hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial AT schafersimont hypoxiainduciblefactor1alphaandprolinhydroxlase2polymorphismsinpatientswithseveresepsisaprospectiveobservationaltrial |